1
|
Abstract
Finding out predisposition and makeup alterations in cancer cells has prompted the exploration of exogenous small interference RNA (siRNA) as a therapeutic agent to deal with cancer. siRNA is subjected to many limitations that hinders its cellular uptake. Various nanocarriers have been loaded with siRNA to improve their cellular transportation and have moved to clinical trials. However, many restrictions as low encapsulation efficiency, nanocarrier cytotoxicity and premature release of siRNA have impeded the single nanocarrier use. The realm of nanohybrid systems has emerged to overcome these limitations and to synergize the criteria of two or more nanocarriers. Different nanohybrid systems that were developed as cellular pathfinders for the exogenous siRNA to target cancer will be illustrated in this review.
Collapse
|
2
|
Zhang H, Bussmann J, Huhnke FH, Devoldere J, Minnaert A, Jiskoot W, Serwane F, Spatz J, Röding M, De Smedt SC, Braeckmans K, Remaut K. Together is Better: mRNA Co-Encapsulation in Lipoplexes is Required to Obtain Ratiometric Co-Delivery and Protein Expression on the Single Cell Level. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2022; 9:e2102072. [PMID: 34913603 PMCID: PMC8811815 DOI: 10.1002/advs.202102072] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 10/27/2021] [Indexed: 06/14/2023]
Abstract
Liposomes can efficiently deliver messenger RNA (mRNA) into cells. When mRNA cocktails encoding different proteins are needed, a considerable challenge is to efficiently deliver all mRNAs into the cytosol of each individual cell. In this work, two methods are explored to co-deliver varying ratiometric doses of mRNA encoding red (R) or green (G) fluorescent proteins and it is found that packaging mRNAs into the same lipoplexes (mingle-lipoplexes) is crucial to efficiently deliver multiple mRNA types into the cytosol of individual cells according to the pre-defined ratio. A mixture of lipoplexes containing only one mRNA type (single-lipoplexes), however, seem to follow the "first come - first serve" principle, resulting in a large variation of R/G uptake and expression levels for individual cells leading to ratiometric dosing only on the population level, but rarely on the single-cell level. These experimental observations are quantitatively explained by a theoretical framework based on the stochasticity of mRNA uptake in cells and endosomal escape of mingle- and single-lipoplexes, respectively. Furthermore, the findings are confirmed in 3D retinal organoids and zebrafish embryos, where mingle-lipoplexes outperformed single-lipoplexes to reliably bring both mRNA types into single cells. This benefits applications that require a strict control of protein expression in individual cells.
Collapse
Affiliation(s)
- Heyang Zhang
- Laboratory of General Biochemistry and Physical PharmacyFaculty of Pharmaceutical SciencesGhent UniversityGhent9000Belgium
| | - Jeroen Bussmann
- Division of BioTherapeuticsLeiden Academic Center for Drug ResearchLeiden UniversityLeiden2333 CCThe Netherlands
| | - Florian H. Huhnke
- Max Planck Institute for Medical ResearchDepartment of Cellular Biophysics70569StuttgartGermany
| | - Joke Devoldere
- Laboratory of General Biochemistry and Physical PharmacyFaculty of Pharmaceutical SciencesGhent UniversityGhent9000Belgium
| | - An‐Katrien Minnaert
- Laboratory of General Biochemistry and Physical PharmacyFaculty of Pharmaceutical SciencesGhent UniversityGhent9000Belgium
| | - Wim Jiskoot
- Division of BioTherapeuticsLeiden Academic Center for Drug ResearchLeiden UniversityLeiden2333 CCThe Netherlands
| | - Friedhelm Serwane
- Max Planck Institute for Medical ResearchDepartment of Cellular Biophysics70569StuttgartGermany
- Center for NanoScienceLudwig‐Maximilian‐University MunichD‐80333MunichGermany
- Faculty of PhysicsLudwig‐Maximilian‐UniversityD‐80539MunichGermany
- Munich Cluster for Systems Neurology (SyNergy)D‐81377MunichGermany
| | - Joachim Spatz
- Max Planck Institute for Medical ResearchDepartment of Cellular Biophysics70569StuttgartGermany
- Department of Biophysical ChemistryUniversity of Heidelberg69120HeidelbergGermany
| | - Magnus Röding
- RISE Research Institutes of SwedenBioeconomy and Health, Agriculture and FoodGöteborg41276Sweden
- Department of Mathematical SciencesChalmers University of Technology and University of GothenburgGöteborg41296Sweden
| | - Stefaan C. De Smedt
- Laboratory of General Biochemistry and Physical PharmacyFaculty of Pharmaceutical SciencesGhent UniversityGhent9000Belgium
- Cancer Research Institute Ghent (CRIG)Ghent UniversityGhent9000Belgium
| | - Kevin Braeckmans
- Laboratory of General Biochemistry and Physical PharmacyFaculty of Pharmaceutical SciencesGhent UniversityGhent9000Belgium
- Center for Advanced Light MicroscopyGhent UniversityGhent9000Belgium
| | - Katrien Remaut
- Laboratory of General Biochemistry and Physical PharmacyFaculty of Pharmaceutical SciencesGhent UniversityGhent9000Belgium
- Cancer Research Institute Ghent (CRIG)Ghent UniversityGhent9000Belgium
| |
Collapse
|
3
|
Nazari M, Minai-Tehrani A, Mousavi S, Zamani Koukhaloo S, Emamzadeh R. Development of recombinant biomimetic nano-carrier for targeted gene transfer to HER3 positive breast cancer. Int J Biol Macromol 2021; 189:948-955. [PMID: 34455002 DOI: 10.1016/j.ijbiomac.2021.08.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 08/19/2021] [Accepted: 08/20/2021] [Indexed: 12/09/2022]
Abstract
Human epidermal growth factor receptor 3 (HER3) has rapidly gained much attention as a promising target for cancer treatment. The increasing recognition of HER3 roles in a number of HER family-driven cancers has led to studies aimed at targeting this receptor and developing HER3-targeted platforms with the ability to deliver therapeutic genes. We have previously indicated that the flexible linker and one unit of RALA in affibody-based platform could target HER3 and deliver its cargo. Based on the previous finding, in a new class of affibody-based platforms, we used two different linkers and RALA units and then compared their effectiveness on targeting and delivering specified genes to HER3 positive cells. Our results clearly showed that our biopolymeric platforms can successfully condense DNA into nanoparticles and object the overexpressed HER3 receptors and then transfer specific genes. Our affibody-based platform containing a rigid linker and one RALA unit presents an adequate transfection efficacy and low toxicity (based on MTT and apoptosis assays), however, the platform containing two RALA units and a flexible linker demonstrated high transfection efficacy while having modest toxicity in HER3 positive breast cancer cells. This may pave the way for further innovative applications of recombinant biopolymer when stable and economical productions need to be definitely considered.
Collapse
Affiliation(s)
- Mahboobeh Nazari
- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
| | - Arash Minai-Tehrani
- Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
| | - Samira Mousavi
- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
| | | | - Rahman Emamzadeh
- Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
| |
Collapse
|
4
|
Cheraghi R, Nazari M, Alipour M, Hosseinkhani S. Stepwise Development of Biomimetic Chimeric Peptides for Gene Delivery. Protein Pept Lett 2020; 27:698-710. [PMID: 32026767 DOI: 10.2174/0929866527666200206153328] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 09/23/2019] [Accepted: 11/07/2019] [Indexed: 11/22/2022]
Abstract
Gene-based therapy largely relies on the vector type that allows a selective and efficient transfection into the target cells with maximum efficacy and minimal toxicity. Although, genes delivered utilizing modified viruses transfect efficiently and precisely, these vectors can cause severe immunological responses and are potentially carcinogenic. A promising method of overcoming this limitation is the use of non-viral vectors, including cationic lipids, polymers, dendrimers, and peptides, which offer potential routes for compacting DNA for targeted delivery. Although non-viral vectors exhibit reduced transfection efficiency compared to their viral counterpart, their superior biocompatibility, non-immunogenicity and potential for large-scale production make them increasingly attractive for modern therapy. There has been a great deal of interest in the development of biomimetic chimeric peptides. Biomimetic chimeric peptides contain different motifs for gene translocation into the nucleus of the desired cells. They have motifs for gene targeting into the desired cell, condense DNA into nanosize particles, translocate the gene into the nucleus and enhance the release of the particle into the cytoplasm. These carriers were developed in recent years. This review highlights the stepwise development of the biomimetic chimeric peptides currently being used in gene delivery.
Collapse
Affiliation(s)
- Roya Cheraghi
- Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
| | - Mahboobeh Nazari
- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
| | - Mohsen Alipour
- Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
| | - Saman Hosseinkhani
- Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
| |
Collapse
|
5
|
Cellulose Nanofibers and Other Biopolymers for Biomedical Applications. A Review. APPLIED SCIENCES-BASEL 2019. [DOI: 10.3390/app10010065] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Biopolymers are materials synthesised or derived from natural sources, such as plants, animals, microorganisms or any other living organism. The use of these polymers has grown significantly in recent years as industry shifts away from unsustainable fossil fuel resources and looks towards a softer and more sustainable environmental approach. This review article covers the main classes of biopolymers: Polysaccharides, proteins, microbial-derived and lignin. In addition, an overview of the leading biomedical applications of biopolymers is also provided, which includes tissue engineering, medical implants, wound dressings, and the delivery of bioactive molecules. The future clinical applications of biopolymers are vast, due to their inherent biocompatibility, biodegradability and low immunogenicity. All properties which their synthetic counterparts do not share.
Collapse
|
6
|
Nazari M, Zamani Koukhaloo S, Mousavi S, Minai‐Tehrani A, Emamzadeh R, Cheraghi R. Development of a ZHER3‐Affibody‐Targeted Nano‐Vector for Gene Delivery to HER3‐Overexpressed Breast Cancer Cells. Macromol Biosci 2019; 19:e1900159. [DOI: 10.1002/mabi.201900159] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 08/14/2019] [Indexed: 12/24/2022]
Affiliation(s)
- Mahboobeh Nazari
- Monoclonal Antibody Research CenterAvicenna Research InstituteACECR Tehran 1936773493 Iran
| | | | - Samira Mousavi
- Monoclonal Antibody Research CenterAvicenna Research InstituteACECR Tehran 1936773493 Iran
| | - Arash Minai‐Tehrani
- Nanobiotechnology Research CenterAvicenna Research InstituteACECR Tehran 1936773493 Iran
| | - Rahman Emamzadeh
- Department of BiologyFaculty of SciencesUniversity of Isfahan Isfahan 8174673441 Iran
| | - Roya Cheraghi
- Department of NanobiotechnologyFaculty of Biological SciencesTarbiat Modares University Tehran 111‐14115 Iran
| |
Collapse
|
7
|
Bai X, Kong M, Wu X, Feng C, Park H, Chen X. A multi-responsive biomimetic nano-complex platform for enhanced gene delivery. J Mater Chem B 2018; 6:5910-5921. [DOI: 10.1039/c8tb02038h] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
RNA interference (RNAi) is widely regarded as a promising technology for disease treatment, yet one major obstacle for its clinical application is the lack of enhanced siRNA delivery vehicles to circumvent complex extra- and intracellular barriers.
Collapse
Affiliation(s)
- Xiaoyu Bai
- College of Marine Life Science
- Ocean University of China
- Qingdao
- P. R. China
| | - Ming Kong
- College of Marine Life Science
- Ocean University of China
- Qingdao
- P. R. China
| | - Xuanjin Wu
- College of Marine Life Science
- Ocean University of China
- Qingdao
- P. R. China
| | - Chao Feng
- College of Marine Life Science
- Ocean University of China
- Qingdao
- P. R. China
| | - Hyunjin Park
- Graduate School Biotechnology
- Korea University
- Seoul 136-701
- South Korea
| | - Xiguang Chen
- College of Marine Life Science
- Ocean University of China
- Qingdao
- P. R. China
| |
Collapse
|
8
|
Chen X, Nomani A, Patel N, Nouri FS, Hatefi A. Bioengineering a non-genotoxic vector for genetic modification of mesenchymal stem cells. Biomaterials 2018; 152:1-14. [PMID: 29078136 PMCID: PMC5671363 DOI: 10.1016/j.biomaterials.2017.10.028] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Revised: 09/22/2017] [Accepted: 10/17/2017] [Indexed: 01/14/2023]
Abstract
Vectors used for stem cell transfection must be non-genotoxic, in addition to possessing high efficiency, because they could potentially transform normal stem cells into cancer-initiating cells. The objective of this research was to bioengineer an efficient vector that can be used for genetic modification of stem cells without any negative somatic or genetic impact. Two types of multifunctional vectors, namely targeted and non-targeted were genetically engineered and purified from E. coli. The targeted vectors were designed to enter stem cells via overexpressed receptors. The non-targeted vectors were equipped with MPG and Pep1 cell penetrating peptides. A series of commercial synthetic non-viral vectors and an adenoviral vector were used as controls. All vectors were evaluated for their efficiency and impact on metabolic activity, cell membrane integrity, chromosomal aberrations (micronuclei formation), gene dysregulation, and differentiation ability of stem cells. The results of this study showed that the bioengineered vector utilizing VEGFR-1 receptors for cellular entry could transfect mesenchymal stem cells with high efficiency without inducing genotoxicity, negative impact on gene function, or ability to differentiate. Overall, the vectors that utilized receptors as ports for cellular entry (viral and non-viral) showed considerably better somato- and genosafety profiles in comparison to those that entered through electrostatic interaction with cellular membrane. The genetically engineered vector in this study demonstrated that it can be safely and efficiently used to genetically modify stem cells with potential applications in tissue engineering and cancer therapy.
Collapse
Affiliation(s)
- Xuguang Chen
- Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA
| | - Alireza Nomani
- Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA
| | - Niket Patel
- Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA
| | - Faranak S Nouri
- Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA
| | - Arash Hatefi
- Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
| |
Collapse
|
9
|
Hatefi A, Karjoo Z, Nomani A. Development of a Recombinant Multifunctional Biomacromolecule for Targeted Gene Transfer to Prostate Cancer Cells. Biomacromolecules 2017; 18:2799-2807. [PMID: 28806522 DOI: 10.1021/acs.biomac.7b00739] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The objective of this study was to genetically engineer a fully functional single chain fusion peptide composed of motifs from diverse biological and synthetic origins that can perform multiple tasks including DNA condensation, cell targeting, cell transfection, particle shielding from immune system and effective gene transfer to prostate tumors. To achieve the objective, a single chain biomacromolecule (vector) consisted of four repeatative units of histone H2A peptide, fusogenic peptide GALA, short elastin-like peptide, and PC-3 cell targeting peptide was designed. To examine the functionality of each motif in the vector sequence, it was characterized in terms of size and zeta potential by Zetasizer, PC-3 cell targeting and transfection by flowcytometry, IgG induction by immunogenicity assay, and PC-3 tumor transfection by quantitative live animal imaging. Overall, the results of this study showed the possibility of using genetic engineering techniques to program various functionalities into one single chain vector and create a multifunctional nonimmunogenic biomacromolecule for targeted gene transfer to prostate cancer cells. This proof-of-concept study is a significant step forward toward creating a library of vectors for targeted gene transfer to any cancer cell type at both in vitro and in vivo levels.
Collapse
Affiliation(s)
- Arash Hatefi
- Department of Pharmaceutics, Rutgers The State University of New Jersey , Piscataway, New Jersey 08854, United States.,Rutgers Cancer Institute of New Jersey , New Brunswick, New Jersey 08903, United States
| | - Zahra Karjoo
- Department of Pharmaceutics, Rutgers The State University of New Jersey , Piscataway, New Jersey 08854, United States
| | - Alireza Nomani
- Department of Pharmaceutics, Rutgers The State University of New Jersey , Piscataway, New Jersey 08854, United States
| |
Collapse
|
10
|
Zhang YM, Huang Z, Zhang J, Wu WX, Liu YH, Yu XQ. Amphiphilic polymers formed from ring-opening polymerization: a strategy for the enhancement of gene delivery. Biomater Sci 2017; 5:718-729. [DOI: 10.1039/c6bm00859c] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Ring-opening polymerization was found to be a promising strategy to improve the transfection efficiency and serum tolerance of cationic lipids.
Collapse
Affiliation(s)
- Yi-Mei Zhang
- Key Laboratory of Green Chemistry and Technology (Ministry of Education)
- College of Chemistry
- Sichuan University
- Chengdu 610064
- PR China
| | - Zheng Huang
- Key Laboratory of Green Chemistry and Technology (Ministry of Education)
- College of Chemistry
- Sichuan University
- Chengdu 610064
- PR China
| | - Ji Zhang
- Key Laboratory of Green Chemistry and Technology (Ministry of Education)
- College of Chemistry
- Sichuan University
- Chengdu 610064
- PR China
| | - Wan-Xia Wu
- Key Laboratory of Green Chemistry and Technology (Ministry of Education)
- College of Chemistry
- Sichuan University
- Chengdu 610064
- PR China
| | - Yan-Hong Liu
- Key Laboratory of Green Chemistry and Technology (Ministry of Education)
- College of Chemistry
- Sichuan University
- Chengdu 610064
- PR China
| | - Xiao-Qi Yu
- Key Laboratory of Green Chemistry and Technology (Ministry of Education)
- College of Chemistry
- Sichuan University
- Chengdu 610064
- PR China
| |
Collapse
|
11
|
Martínez-Negro M, Kumar K, Barrán-Berdón AL, Datta S, Kondaiah P, Junquera E, Bhattacharya S, Aicart E. Efficient Cellular Knockdown Mediated by siRNA Nanovectors of Gemini Cationic Lipids Having Delocalizable Headgroups and Oligo-Oxyethylene Spacers. ACS APPLIED MATERIALS & INTERFACES 2016; 8:22113-22126. [PMID: 27508330 DOI: 10.1021/acsami.6b08823] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The use of small interfering RNAs (siRNAs) to silence specific genes is one of the most promising approaches in gene therapy, but it requires efficient nanovectors for successful cellular delivery. Recently, we reported liposomal gene carriers derived from a gemini cationic lipid (GCL) of the 1,2-bis(hexadecyl dimethyl imidazolium) oligo-oxyethylene series ((C16Im)2(C2H4O)nC2H4 with n = 1, 2, or 3) and 1,2-dioleyol phosphatidylethanolamine as highly efficient cytofectins for pDNA. On the basis of the satisfactory outcomes of the previous study, the present work focuses on the utility of coliposomes of these gemini lipids with the biocompatible neutral lipid mono oleoyl glycerol (MOG) as highly potent vectors for siRNA cellular transport in the presence of serum. The (C16Im)2(C2H4O)nC2H4/MOG-siRNA lipoplexes were characterized through (i) a physicochemical study (zeta potential, cryo-transmission electron microscopy, small-angle X-ray scattering, and fluorescence anisotropy) to establish the relationship between size, structure, fluidity, and the interaction between siRNA and the GCL/MOG gene vectors and (ii) a biological analysis (flow cytometry, fluorescence microscopy, and cell viability) to report the anti-GFP siRNA transfections in HEK 293T, HeLa, and H1299 cancer cell lines. The in vitro biological analysis confirms the cellular uptake and indicates that a short spacer, a very low molar fraction of GCL in the mixed lipid, and a moderate effective charge ratio of the lipoplex yielded maximum silencing efficacy. At these experimental conditions, the siRNA used in this work is compacted by the GCL/MOG nanovectors by forming two cubic structures (Ia3d and Pm3n) that are correlated with excellent silencing activity. These liposomal nanocarriers possess high silencing activity with a negligible cytotoxicity, which strongly supports their practical use for in vivo knockdown studies.
Collapse
Affiliation(s)
- María Martínez-Negro
- Grupo de Química Coloidal y Supramolecular, Departamento de Química Física I, Facultad de Ciencias Químicas, Universidad Complutense de Madrid , 28040 Madrid, Spain
| | | | - Ana L Barrán-Berdón
- Grupo de Química Coloidal y Supramolecular, Departamento de Química Física I, Facultad de Ciencias Químicas, Universidad Complutense de Madrid , 28040 Madrid, Spain
| | | | | | - Elena Junquera
- Grupo de Química Coloidal y Supramolecular, Departamento de Química Física I, Facultad de Ciencias Químicas, Universidad Complutense de Madrid , 28040 Madrid, Spain
| | | | - Emilio Aicart
- Grupo de Química Coloidal y Supramolecular, Departamento de Química Física I, Facultad de Ciencias Químicas, Universidad Complutense de Madrid , 28040 Madrid, Spain
| |
Collapse
|
12
|
Quan S, Kumar P, Narain R. Cationic Galactose-Conjugated Copolymers for Epidermal Growth Factor (EGFR) Knockdown in Cervical Adenocarcinoma. ACS Biomater Sci Eng 2016; 2:853-859. [DOI: 10.1021/acsbiomaterials.6b00085] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Stephen Quan
- Donadeo Innovation Centre for Engineering, Department of Chemical and Materials Engineering, and ‡Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Piyush Kumar
- Donadeo Innovation Centre for Engineering, Department of Chemical and Materials Engineering, and ‡Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Ravin Narain
- Donadeo Innovation Centre for Engineering, Department of Chemical and Materials Engineering, and ‡Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
13
|
McBride JW, Massey AS, McCaffrey J, McCrudden CM, Coulter JA, Dunne NJ, Robson T, McCarthy HO. Development of TMTP-1 targeted designer biopolymers for gene delivery to prostate cancer. Int J Pharm 2016; 500:144-53. [DOI: 10.1016/j.ijpharm.2016.01.039] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Revised: 01/13/2016] [Accepted: 01/14/2016] [Indexed: 02/03/2023]
|
14
|
Nouri FS, Wang X, Chen X, Hatefi A. Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides. Pharm Res 2015; 32:3018-28. [DOI: 10.1007/s11095-015-1683-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Accepted: 03/18/2015] [Indexed: 01/21/2023]
|
15
|
Li Y, Liu R, Shi Y, Zhang Z, Zhang X. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon. Theranostics 2015; 5:583-96. [PMID: 25825598 PMCID: PMC4377727 DOI: 10.7150/thno.11234] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 01/23/2015] [Indexed: 12/28/2022] Open
Abstract
For efficient delivery of small interfering RNA (siRNA) to the target diseased site in vivo, it is important to design suitable vehicles to control the blood circulation of siRNA. It has been shown that surface modification of cationic liposome/siRNA complexes (lipoplexes) with polyethylene glycol (PEG) could enhance the circulation time of lipoplexes. However, the first injection of PEGylated lipoplexes in vivo induces accelerated blood clearance and enhances hepatic accumulation of the following injected PEGylated lipoplexes, which is known as the accelerated blood clearance (ABC) phenomenon. Herein, we developed zwitterionic poly(carboxybetaine) (PCB) modified lipoplexes for the delivery of siRNA therapeutics, which could avoid protein adsorption and enhance the stability of lipoplexes as that for PEG. Quite different from the PEGylation, the PCBylated lipoplexes could avoid ABC phenomenon, which extended the blood circulation time and enhanced the tumor accumulation of lipoplexes in vivo. After accumulation in tumor site, the PCBylation could promote the cellular uptake and endosomal/lysosomal escape of lipoplexes due to its unique chemical structure and pH-sensitive ability. With excellent tumor accumulation, cellular uptake and endosomal/lysosomal escape abilities, the PCBylated lipoplexes significantly inhibited tumor growth and induced tumor cell apoptosis.
Collapse
|
16
|
Price R, Poursaid A, Ghandehari H. Controlled release from recombinant polymers. J Control Release 2014; 190:304-13. [PMID: 24956486 PMCID: PMC4142100 DOI: 10.1016/j.jconrel.2014.06.016] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2014] [Revised: 06/10/2014] [Accepted: 06/13/2014] [Indexed: 12/13/2022]
Abstract
Recombinant polymers provide a high degree of molecular definition for correlating structure with function in controlled release. The wide array of amino acids available as building blocks for these materials lend many advantages including biorecognition, biodegradability, potential biocompatibility, and control over mechanical properties among other attributes. Genetic engineering and DNA manipulation techniques enable the optimization of structure for precise control over spatial and temporal release. Unlike the majority of chemical synthetic strategies used, recombinant DNA technology has allowed for the production of monodisperse polymers with specifically defined sequences. Several classes of recombinant polymers have been used for controlled drug delivery. These include, but are not limited to, elastin-like, silk-like, and silk-elastinlike proteins, as well as emerging cationic polymers for gene delivery. In this article, progress and prospects of recombinant polymers used in controlled release will be reviewed.
Collapse
Affiliation(s)
- Robert Price
- Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, USA
| | - Azadeh Poursaid
- Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, USA; Department of Bioengineering, University of Utah, Salt Lake City, UT, USA
| | - Hamidreza Ghandehari
- Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, USA; Department of Bioengineering, University of Utah, Salt Lake City, UT, USA.
| |
Collapse
|
17
|
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release 2014; 194:238-56. [PMID: 25204288 DOI: 10.1016/j.jconrel.2014.09.001] [Citation(s) in RCA: 251] [Impact Index Per Article: 25.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Revised: 08/29/2014] [Accepted: 09/01/2014] [Indexed: 12/21/2022]
Abstract
Chemotherapeutic agents have certain limitations when it comes to treating cancer, the most important being severe side effects along with multidrug resistance developed against them. Tumor cells exhibit drug resistance due to activation of various cellular level processes viz. activation of drug efflux pumps, anti-apoptotic defense mechanisms, etc. Currently, RNA interference (RNAi) based therapeutic approaches are under vibrant scrutinization to seek cancer cure. Especially small interfering RNA (siRNA) and micro RNA (miRNA), are able to knock down the carcinogenic genes by targeting the mRNA expression, which underlies the uniqueness of this therapeutic approach. Recent research focus in the regime of cancer therapy involves the engagement of targeted delivery of siRNA/miRNA in combinations with other therapeutic agents (such as gene, DNA or chemotherapeutic drug) for targeting permeability glycoprotein (P-gp), multidrug resistant protein 1 (MRP-1), B-cell lymphoma (BCL-2) and other targets that are mainly responsible for resistance in cancer therapy. RNAi-chemotherapeutic drug combinations have also been found to be effective against different molecular targets as well and can increase the sensitization of cancer cells to therapy several folds. However, due to stability issues associated with siRNA/miRNA suitable protective carrier is needed and nanotechnology based approaches have been widely explored to overcome these drawbacks. Furthermore, it has been univocally advocated that the co-delivery of siRNA/miRNA with other chemodrugs significantly enhances their capability to overcome cancer resistance compared to naked counterparts. The objective of this article is to review recent nanocarrier based approaches adopted for the delivery of siRNA/miRNA combinations with other anticancer agents (siRNA/miRNA/pDNA/chemodrugs) to treat cancer.
Collapse
|
18
|
Li Y, Cheng Q, Jiang Q, Huang Y, Liu H, Zhao Y, Cao W, Ma G, Dai F, Liang X, Liang Z, Zhang X. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA. J Control Release 2014; 176:104-14. [DOI: 10.1016/j.jconrel.2013.12.007] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2013] [Revised: 11/22/2013] [Accepted: 12/08/2013] [Indexed: 12/17/2022]
|
19
|
Resnier P, Montier T, Mathieu V, Benoit JP, Passirani C. A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 2013; 34:6429-43. [PMID: 23727262 DOI: 10.1016/j.biomaterials.2013.04.060] [Citation(s) in RCA: 156] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2013] [Accepted: 04/27/2013] [Indexed: 12/11/2022]
Abstract
RNA interference currently offers new opportunities for gene therapy by the specific extinction of targeted gene(s) in cancer diseases. However, the main challenge for nucleic acid delivery still remains its efficacy through intravenous administration. Over the last decade, many delivery systems have been developed and optimized to encapsulate siRNA and to specifically promote their delivery into tumor cells and improve their pharmacokinetics for anti-cancer purposes. This review aims to sum up the potential targets in numerous pathways and the properties of recently optimized siRNA synthetic nanomedicines with their preclinical applications and efficacy. Future perspectives in cancer treatment are discussed including promising concomitant treatment with chemotherapies or other siRNA. The outcomes in human clinical trials are also presented.
Collapse
|
20
|
Wu ZW, Chien CT, Liu CY, Yan JY, Lin SY. Recent progress in copolymer-mediated siRNA delivery. J Drug Target 2012; 20:551-60. [DOI: 10.3109/1061186x.2012.699057] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
21
|
Frandsen JL, Ghandehari H. Recombinant protein-based polymers for advanced drug delivery. Chem Soc Rev 2012; 41:2696-706. [DOI: 10.1039/c2cs15303c] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
22
|
Wang Y, Chen J, Irudayaraj J. Nuclear targeting dynamics of gold nanoclusters for enhanced therapy of HER2+ breast cancer. ACS NANO 2011; 5:9718-25. [PMID: 22053819 DOI: 10.1021/nn2032177] [Citation(s) in RCA: 170] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Recent advances in fluorescent metal nanoclusters have spurred tremendous interest in nanomedicine due to the ease of fabrication, excellent biocompatibility, and, more importantly, excellent wavelength-dependent tunability. Herein, we report our findings on fluorescent BSA-protected gold nanoclusters (AuNCs), ∼2 nm in size conjugated with Herceptin (AuNCs-Her), for specific targeting and nuclear localization in ErbB2 over-expressing breast cancer cells and tumor tissue as a novel fluorescent agent for simultaneous imaging and cancer therapy. More interestingly, we found that AuNCs-Her could escape the endolysosomal pathway and enter the nucleus of cancer cells to enhance the therapeutic efficacy of Herceptin. We elucidate the diffusion characteristics (diffusion time and number of diffusers) and concentration of the fluorescing clusters in the nucleus of live cells. Our findings also suggest that the nuclear localization effect of AuNCs-Her enhances the anticancer therapeutic efficacy of Herceptin as evidenced by the induction of DNA damage. This study not only discusses a new nanomaterial platform for nuclear delivery of drugs but also provides important insights on nuclear targeting for enhanced therapy.
Collapse
Affiliation(s)
- Yuling Wang
- Bindley Bioscience Center, Department of Agricultural and Biological Engineering, 225 South University Street, Purdue University, West Lafayette, Indiana 47907, United States
| | | | | |
Collapse
|
23
|
Suicide gene therapy using reducible poly (oligo-D-arginine) for the treatment of spinal cord tumors. Biomaterials 2011; 32:9766-75. [PMID: 21924768 DOI: 10.1016/j.biomaterials.2011.08.089] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Accepted: 08/31/2011] [Indexed: 11/21/2022]
Abstract
Suicide gene therapy based on a combination of herpes simplex virus-thymidine kinase (HSV-tk) and ganciclovir (GCV) has obstacles to achieving a success in clinical use for the treatment of cancer due to inadequate thymidine kinase (TK) expression. The primary concern for improving anticancer efficacy of the suicide gene therapy is to develop an appropriate carrier that highly expresses TK in vivo. Despite great advances in the development of non-viral vectors, none has been used in cancer suicide gene therapy, not even in experimental challenge. Reducible poly (oligo-D-arginine) (rPOA), one of the effective non-viral carriers working in vivo, was chosen to deliver HSV-tk to spinal cord tumors which are appropriate targets for suicide gene therapy. Since the system exerts toxicity only in dividing cells, cells in the central nervous system, which are non-proliferative, are not sensitive to the toxic metabolites. In the present study, we demonstrated that the locomotor function of the model rat was maintained through the tumor suppression resulting from the tumor-selective suicide activity by co-administration of rPOA/HSV-tk and GCV. Thus, rPOA plays a crucial role in suicide gene therapy for cancer, and an rPOA/HSV-tk and GCV system could help promote in vivo trials of suicide gene therapy.
Collapse
|